AstraZeneca, Daiichi Sankyo's Enhertu Gets Breakthrough Therapy Designation in the US
I'm PortAI, I can summarize articles.
05:12 AM EST, 12/22/2025 (MT Newswires) -- AstraZeneca ( AZN ) and Daiichi Sankyo said Monday its jointly developed and commercialized antibody drug conjugate, Enhertu, has been granted breakthrough therapy designation by the US Food and Drug Administration for adults with a certain type of breast cancer.The designation was granted based on results from a phase 3 trial, the company said. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
Source: fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments